Ribavirin for chronic hepatitis E virus infection

New England Journal of Medicine

Volumn 370, Issue 25, 2014, Pages 2447-

  Lee, Kuan Yeh ^a   Hung, Chien Ching ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS E VACCINE; HEV 239; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; RIBAVIRIN;

CHINESE; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HEPATITIS A; HEPATITIS E; HEPATITIS E VIRUS; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LETTER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; VACCINATION; VIRUS GENE; FEMALE; MALE; NOTE; ORGAN TRANSPLANTATION;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS E; HUMANS; MALE; ORGAN TRANSPLANTATION; RIBAVIRIN;

EID: 84902585766     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1405191     Document Type: Letter

References (3)

1. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-7. (Pubitemid 351281642)
2. Danziger-Isakov L, Kumar D. Vaccination in solid organ transplantation. Am J Transplant 2013;13:Suppl 4:311-7.
3. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895-902.